Stabilitech BioPharma

Redefining the way we make and take vaccines.  

PLATFORM LICENSING

 

ORAPRO-ZIKA

ORAPRO-COVID-19

THERM-SB

 

COVID-19

  • Millions of people infected.
  • Billions of people affected.
  • Trillions of dollars invested.

The world is fighting back.

Stabilitech is part of that fight.

The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.

The Los Angeles Times’ Ralph Vartabedian says:

“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”

Thermally stable, self-administered vaccines in capsule form are the future

 

ORAPRO™

Imagine a world where all vaccines are taken as a capsule – with no needles, no need for cold storage and reduced dependency on healthcare professionals.

OraPro™ is an oral delivery vaccine platform. It effectively delivers non-replicating viral vectors to the gastrointestinal (GI) tract to elicit effective immunity against infectious diseases but not the viral vector itself. Stabilitech is using OraPro to develop the world’s first oral COVID-19 and Zika vaccines. Research is also underway to develop oral vaccines for several other key diseases, including OraPro-Shingles to provide immunity to the Varicela Zoster Virus, which is affects 1 in 4 adults in their lifetime and was estimated to be worth $2 billion in 2019.

Discover more about OraPro and our oral vaccine development programme

ORAPRO-COVID-19

COVID-19 is the perfect example of a novel virus with the ability to rapidly cause a pandemic. In the case of a highly infectious novel virus, the swift development of a vaccine is not enough. An effective vaccine needs to deliver mucosal and systemic immunity combined with how quickly an entire population can be vaccinated.

Using OraPro technology, Stabilitech’s OraPro-COVID-19 can be developed within a matter of weeks. The viral vector can be developed within days and a capsule ready for animal testing can be ready within weeks. These stages are now complete, with clinical trials due to begin, pending securing funding. Because OraPro-COVID-19 is delivered in thermally stable capsules, it can be self-administered by patients without the need for needles and healthcare professionals. The delivery mechanism eliminates the risk of potentially infected people queuing for injections, removes the need for cold-chain delivery and enables the world’s most rapid deployment of vaccines.

Discover more about OraPro-COVID-19™

 

Novel oral protein therapeutic
Multi-strain influenza vaccine
VZV product exempler
Reduce antigen requirement
by up to 99%
Thermally stable vaccines
Faster onset of immunity
using less vaccine

Stabilitech Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19

PRESS RELEASE

 

Stabilitech Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19

Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has today announced that Professor Jeffrey Almond will be joining the board as they step up their efforts in search of a vaccine for COVID-19.

Professor Almond is an Oxford Martin Visiting Fellow with the Oxford Martin Programme on Vaccines and Former Vice President, Head of Discovery Research and External R&D at Sanofi Pasteur and Visiting Professor at the William School of Pathology, University of Oxford. He has been published extensively, especially in the field of virology.

Wayne Channon, Chairman of Stabilitech, commented: “I’m really excited by Professor Almond’s appointment. He brings with him a wealth of knowledge and expertise in developing successful vaccines and I am confident that his knowledge will strengthen our team.”

Speaking about his appointment, Professor Almond stated: “I am delighted to be joining the board and working with like-minded professionals using Stabilitech’s unique stabilisation technology. COVID-19 is a unique disease, and so at Stabilitech we have taken a unique approach. Ours is currently the only stabilised oral vaccine in development, meaning it targets both systemic and mucosal immunity, crucial for effective widespread immunisation against COVID-19.”

Stabilitech’s bid to find £6m to further develop their innovative oral capsule OraPro-COVID-19 means Almond’s appointment is timely. His previous work includes the completion of the genetic map of an avian influenza virus, the first detailed description of the proteins of Influenza B virus, and determination of the genetic basis of attenuation of the oral polio vaccine.

For more information on the science behind OraPro-COVID-19, or for interviews with Professor Jeffery Almond or, Wayne Channon, please email: Stabilitech@copestone.uk.com

End of press release (289 words)

Downloadable media assets

Press release docFull Zip Download
Stabilitech Biopharma strengthens leadership team, as Jeffrey Almond joins the board in the race to develop oral vaccine for COVID-19Stabilitech_press_release_media_downloadStabilitech Logo

Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules

PRESS RELEASE

 

Stabilitech Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules

Burgess Hill, UK, 30 April 2020 STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today that, it is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19.

“Delivering a COVID-19 vaccine in the shortest time possible is only half the challenge,” highlight’s Stabilitech’s Chairman, Wayne Channon. “delivering a vaccine that works is more important. COVID-19 infects the mucous membranes, or linings, of the ear, nose throat and lungs. That is why we are targeting our vaccine to hit COVID-19 where it sits – in mucosal cells. Other vaccines are currently only targeting the systemic immune system, but we know from our research that COVID -19 is a mucosal virus, therefore all vaccine developers should also be looking for a vaccine that targets both mucosal and systemic immunity. This is what OraPro- COVID-19 delivers in a single capsule.”

According to Channon, Stabilitech’s unique OraPro-COVID-19 capsules contain a freeze-dried COVID-19 vaccine and are thermally stable, which means they do not need refrigeration, as most other vaccines do. It can be simply mailed and self-administered: “Even the most vulnerable and shielded can benefit without a high risk visit to a healthcare professional. The unique benefit of this vaccine is that it can be self- administered, meaning that once it has been delivered via post, you can simply swallow the capsule. No injections, no needles, no nurse or doctor’s visit, therefore no need for PPE that’s still in such short supply. And no expensive cold-chain storage is required like most other vaccines currently under development.”

So, how does this seemingly too-good-to-be-true technology work? Stabilitech’s founder and Chief Scientific Officer Dr Jeff Drew (a virologist who has over 40 biotech patents to his name), explains: “To generate protective immunity, first we insert the Spike-protein DNA from COVID-19, the S-protein cargo, into a non-replicating adenovirus, the viral vector. OraPro’s thermal stability technology is applied and packaged within an acid resistant capsule that protects the vaccine as it passes through the stomach before being dissolved in the gut. Because it is thermally stable, the vaccine is unharmed by the high – 37 degrees centigrade – temperatures in the stomach.

“The viral vector delivers the S-protein cargo DNA to mucosal intestinal cells, which produce copies of the COVID-19 S-protein. These cells deliver the S-protein to the cell membrane that results in mucosal and systemic immunity. It takes two to three weeks for the immunity to develop.”

Initial animal safety trials have been successfully concluded and the next stage of Stabilitech’s OraPro COVID-19 development is clinical trials, under the supervision of the regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).

Trials are set to start in June, and a vaccine could be available by the end of the year. To achieve this, Stabilitech requires £6m in funding for the clinical trials and manufacturing the capsule. InnovateUK requested Stabilitech to repurpose its Zika funding to start the research and development of OraPro-COVID-19 but greater investment is required to finance this next vital stage of development.

“We are confident that the science behind OraPro-COVID-19 works as we’ve seen in our recent project with the Zika Virus vaccine. Conditional on the funding being available for clinical trial, OraPro-COVID-19 can be delivered faster than many other vaccine candidates.”
For further information about the science behind OraPro-COVID-19 and investment opportunities please contact: Stabilitech@copestone.uk.com

End of press release (585 words)

Downloadable media assets

Press release docFull Zip Download
Stabilitech-Biopharma-joins-race-to-develop-COVID-19-vaccine-delivering-unique-double-immunity-using-self-administered-capsuleStabilitech_press_release_media_downloadStabilitech Logo